Cierra Buckman

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Help wanted: Lessons on prevention from young adults with a sexual interest in prepubescent children

Ryan T. Shields, Sarah M. Murray, Amanda E. Ruzicka et al. · Child Abuse & Neglect · 2020 · 43 citations

Public Health, Health Promotion, Pediatrics +10

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas et al. · The Lancet Diabetes & Endocrinology · 2023 · 40 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +11

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

Saul N. Faust, Richard Haynes, Christine E. Jones et al. · The Lancet Child & Adolescent Health · 2024 · 38 citations · Full text

Life Sciences, Immunology, Pediatrics +15